院内协定方消渴3号方对早期糖尿病肾病患者Cys C、SOD、IL-6、hs-crp的改善作用分析

Analysis of Xiaoke 3 on Cys C,SOD,IL-6,hs-crp improvement in patients with early diabetic nephropathy

目的分析消渴3号方对早期糖尿病肾病患者CysC、SOD、IL-6、hs-crp的改善作用。方法本研究选择2018年11月-2020年10月,涉及的研究对象共计92例,将其采用研究对照的形式,分为对照组和观察组,两组患者均采用基础治疗,对照组患者采用的药物为厄贝沙坦,观察组患者则在上述治疗的基础上采用院内协定方消渴3号方。结果观察组患者的治疗效果较高。同时,观察组患者在治疗后的CysC、SOD、IL-6、hs-crp改善情况较为理想,但是两组患者治疗后的治疗后空腹血糖和餐后2h血糖数据不存在差异,观察组患者治疗后的中医证候分值也低于对照组。结论对于早期糖尿病肾病的患者,采用消渴3号方的治疗效果较为理想,能有效改善患者的临床症状,并改善CysC、SOD、IL-6、hs-crp等指标情况。保证患者健康。

Objective To analyze the effect of Xiaoke No.3 prescription on the Cys C、SOD、IL-6、hs-crp of early diabetic nephropathy patients.Methods from November 2018 to October 2020,92 patients were divided into two groups.The control group was treated with irbesartan.The observation group patients on the basis of the above treatment using hospital agreement prescription Xiaoke 3.Results The therapeutic effect of the observation group was higher.Meanwhile,the Cys C、SOD、IL-6、hs-crp improvement of the patients in the observation group after treatment was ideal,but there was no difference between fasting blood glucose and postprandial 2 h blood glucose data after treatment between the two groups.The TCM syndrome score of the observation group was also lower than that of the control group.Conclusion for patients with early diabetic nephropathy,the treatment effect of Xiaoke No.3 prescription is ideal,which can effectively improve the clinical symptoms and Cys C、SOD、IL-6、hs-crp of the patients.Ensure the health of the patient.